Immunophotonics, Inc. — SEC Form D Filing
Immunophotonics, Inc. filed an SEC Form D on September 4, 2026, reporting $10.15M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 4, 2026
- Amount reported
- $10.15M
- Round stage
- Series B because a ten million dollar equity raise typically supports mid-stage clinical trials and pipeline expansion for biotechnology corporations.
- Industry
- Pharmaceuticals
- Website
- https://www.immunophotonics.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Solid tumors and metastatic cancers often evade the immune system, rendering localized treatments ineffective at preventing systemic recurrence.
Solution
Immunophotonics develops a proprietary antigen-presenting cell activator designed to turn a routine tumor ablation procedure into a systemic immunotherapy.
Why now
The rapid clinical adoption of interventional oncology procedures has created an immediate opportunity to integrate localized physical therapies with systemic immunotherapeutic agents.
Source: SEC EDGAR Form D filing